Company intelligence / Profile preview

Enigma Biomedical Group

Toronto, Ontario, Canadaenigmabiomedicalgroup.ca ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has advanced two novel four-repeat tau PET imaging biomarkers into Phase 1 studies for use in neurodegenerative disease research. Previous successful neuroimaging biomarker programs were sold to Lantheus Medical Imaging and Meilleur Technologies Inc. The new candidates are licensed from AbbVie and will be evaluated for safety, dosimetry, uptake dynamics, and clinical utility in PSP patients starting Q3/Q4 of 2025. EBG’s focus remains on enabling precision medicine approaches through advanced molecular imaging tools.

Therapeutic areas: Neurology
Modalities: Radiopharmaceutical (PET imaging biomarkers)Small molecule (as PET tracers are typically small molecules)
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

CBD2115

Pre-clinical

Indications: Progressive Supranuclear Palsy, Corticobasal Degeneration

Partnerships

AbbVie (exclusive license for next-generation F18 PET tracers)Academic institutions/universities globally for research access/collaboration

Beyond the preview

Go deeper on Enigma Biomedical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enigma Biomedical Group.

Explore the full profile